A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress Meeting Abstract
| Authors: | Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; Jain, P.; Barboux, V.; Chisamore, M.; Abshire, M.; Mahboub-Johnson, P.; Hassan, I.; Knipstein, J.; Cloughesy, T. |
| Abstract Title: | A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress |
| Meeting Title: | 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 26 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2024 Nov 21-24 |
| Meeting Location: | Houston, TX |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-11-01 |
| Start Page: | viii89 |
| Language: | English |
| ACCESSION: | WOS:001362477700010 |
| DOI: | 10.1093/neuonc/noae165.0352 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CTIM-19 (Citation ID: NOAE165.0352) -- Source: Wos |
